0000899243-19-002326.txt : 20190201
0000899243-19-002326.hdr.sgml : 20190201
20190201164047
ACCESSION NUMBER: 0000899243-19-002326
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190131
FILED AS OF DATE: 20190201
DATE AS OF CHANGE: 20190201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND
CENTRAL INDEX KEY: 0001743774
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38536
FILM NUMBER: 19560330
MAIL ADDRESS:
STREET 1: C/O XERIS PHARMACEUTICALS, INC.
STREET 2: 180 N. LASALLE STREET, SUITE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001346302
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203352427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 512-498-2670
MAIL ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-31
0
0001346302
XERIS PHARMACEUTICALS INC
XERS
0001743774
JOHNSON KENNETH ERLAND
C/O XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET, SUITE 1810
CHICAGO
IL
60601
0
1
0
0
See Remarks
Stock Option (right to buy)
13.88
2019-01-31
4
A
0
32500
0.00
A
2029-01-31
Common Stock
32500
32500
D
25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months.
Senior Vice President Clinical Development, Quality Assurance, and Medical Affairs
/s/ Beth Hecht, as Attorney-in-Fact
2019-02-01